Navigation Links
Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research
Date:4/20/2009

PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced preliminary data from an ongoing Phase 1 clinical trial of MDX-1401 in patients with relapsed or refractory Hodgkin's lymphoma (HL) that demonstrated both clinical and immunological activity signals. MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers. Results from the study were presented in a poster session (Abstract #1227) at the Annual Meeting of the American Association for Cancer Research (AACR), held April 18-22, 2009 in Colorado.

An ongoing multi-dose, dose-escalation Phase 1 trial of MDX-1401 in patients with relapsed or refractory HL is being conducted to establish and evaluate the safety profile and initial efficacy of MDX-1401. Preliminary data from the Phase 1 trial demonstrate that multiple doses (ranging from 0.01 to 1.0 mg/kg) of MDX-1401 in patients with HL were generally safe and well-tolerated. Two of the 8 patients with stable disease had a reduction of 40 percent or more in tumor burden after two treatment cycles of MDX-1401. In addition, flow cytometry indicated decreased circulating CD30 positive cells in 83 percent of patients (10/12) after one cycle of four weekly intravenous infusions.

"We find these preliminary safety and efficacy data for our second generation anti-CD30 antibody encouraging," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "We are currently enrolling additional patients at higher dose levels and look forward to examining further results from the ongoing Phase 1 trial."

Information about the AACR and its Annual Meeting may be found at www.aacr.org.'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. Medarex Reviews Recent Highlights and Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... WA (PRWEB) May 28, 2015 Senior ... baseball legend Lou Piniella, who managed the Seattle Mariners ... 2001. Piniella will appear in television and digital advertising ... senior living apartment communities, including several new communities slated ... in Bellevue, Bothell, Lynnwood, Mountlake Terrace, Tukwila, and University ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Healthpointe ... will now be offering Echocardiography Examinations to patients ... performed by renowned Qualified Medical Examiner and licensed ... echocardiography test is a non-invasive and cost-effective approach ... are critically ill or have undergone surgery. ...
(Date:5/28/2015)... May 28, 2015 CompanionDx ... company, announces that it will present their integrated ... testing at the annual American Society of Clinical ... sequencing evaluates the DNA in a patient’s tumor ... analyzed for key changes or somatic mutations. Pharmacogenomics ...
(Date:5/28/2015)... Mass. (PRWEB) May 28, 2015 ... $17.5 million round of financing led by Cambia ... solutions company dedicated to transforming health care by creating ... largest and most utilized network for exchanging medical imaging, ... growing customer base, increase the breadth of its network ...
(Date:5/28/2015)... 28, 2015 The drug epidemic has struck ... article published on May 12th, 2015, by Bradenton , ... of time. The first victim, Dylan Besser (21) was a ... the scene. The second overdose victim, Julian Toomsen-Hall (18) was ... the alarming overdose deaths on campus, the college has created ...
Breaking Medicine News(10 mins):Health News:SHAG Announces New Spokesperson: Lou Piniella 2Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4Health News:Two College Campus Deaths Force Sarasota College to Create Drug Task Force 2Health News:Two College Campus Deaths Force Sarasota College to Create Drug Task Force 3
... team headed by Dr. Ian Jackson of University of Edinburgh, ... more readily than blondes or brunettes. The research team has ... The outcome of the research will lead to development of ... gene is still being studied by the researchers, but it ...
... now become a common practice among women these days to ... by a Cesarean Section for religious regions. The trend may ... has found // a link between c-section delivery and higher ... attention regarding the newborns' oral health. This has been the ...
... compromising with the life of its patients and selling expired ... The criminal operation was brought to light // by ... camera. , ,As soon as the accusation was made ... caught. But with evidence staring them in the face they ...
... that increased levels of C-reactive protein in the blood ... ,This finding could lead to new and improved ... as developing drugs that suppress inflammation to improve the ... ,The Mayo Clinic research report appears online and in ...
... eating plenty of fish have been seen in a wealth of ... to a surprising observation – that high fish intake in childhood ... ,Fish Oil is one of the best sources of Omega-3 fatty ... children and adults, and some studies have even pointed to improved ...
... Researchers from Mayo clinic had attributed the rising rates ... increased levels of heparin antibodies in their bodies. , ... Clinic Proceedings // is a preliminary look at one ... In the study, they found patients who had a ...
Cached Medicine News:Health News:Watch out those of you planning for a predetermined Cesarean Section 2Health News:Artery Stiffness Linked To Increasing Levels Of C-reactive protein 2Health News:A Latest Study Links Fish To Stroke 2
(Date:5/28/2015)... , May 28, 2015  Oticon, Inc. is now ... Awards. The national awards program, now in its 17 ... hearing loss who demonstrate that hearing loss does not ... People with any degree of hearing ... eligible. Winners in four categories earn cash prizes, donations ...
(Date:5/28/2015)... 28, 2015 Kindred Biosciences, Inc. (NASDAQ: ... Jennifer Elliott as Vice President of ... Dr. Elliott joins KindredBio from Genentech, where she ... Director of Patent Law.  She had increasing levels ... with Genentech, and most recently oversaw Genentech,s oncology ...
(Date:5/28/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... trial that will also be discussed in an ... Oncology (ASCO) Annual Meeting in Chicago ... superiority study of patients with locally-advanced, nonsquamous non-small ... ®  (pemetrexed for injection), in combination with cisplatin ...
Breaking Medicine Technology:2015 Oticon Focus on People Awards Seek Outstanding People with Hearing Loss For National Recognition and Prizes 2KindredBio Announces Appointment of Jennifer Elliott as Vice President of Legal Affairs and Intellectual Property 2PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 2PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 3PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 4PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 5PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 6PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 7PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 8
... Bioness Inc. today announced that it has received 510(k) ... CE Mark Approval by the European Union for its NESS ... patients to better integrate the NESS H200 into daily life, ... and better outcomes. The NESS H200 Wireless is ...
... Oct. 4, 2011 ReShape Medical®, Inc. today announced ... executive officer.  Interim CEO, Ken Charhut, will continue to ... the board for ReShape Medical.   Previously, ... of Luminous Medical, Inc., an innovative glucose monitoring company ...
Cached Medicine Technology:Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders 2ReShape Medical Names Richard Thompson President and Chief Executive Officer 2
...
... Storage in bottom of tray ... etc. Anodized aluminum. Durable and ... rust. Security locks ensure against ... bumper guards hold instruments in ...
Lance shaped gently curved tip. Flat serrated handle with polished finish....
For use with E0828 A needle tip and E0828 B gouge tip. Round knurled with threaded ended for tips. Most popular size or model....
Medicine Products: